NEJM: A New Drug to Treat 17 Types of Cancer | The Effective Rate is 75%

Recently, the researchers on a study of drugs called larotinide results showed that the drug for the age of 4 months to 76 years of age with 17 different cancer diagnosis of the overall response rate was 75%.

The multidimensional findings of larotrectinib have been published on NEJM on February 21 by Professor David Hong, co-Principal Investigator and David Hyman, head of early drug development at Memorial Sloan-Kettering Cancer Center.

The investigators followed 55 patients with mild adverse events, including three studies in the adult I phase, the child I-II phase, and the adolescent and phase II studies of the elderly. Eligible patients were previously diagnosed as locally advanced or Metastatic solid tumors, received standard treatment, and have the main function of the organ.This study contains 17 kinds of unique cancer diagnosis, including fibrosarcoma in infants (7 cases); mammary gland secreting adenocarcinoma (12 cases); thyroid, colon, lung And gastrointestinal stromal tumors (20 cases); there are 16 other cancer patients.

All patients have tumors of the tropomyosokinin receptor kinase (TRK) fusion gene and mutations in these genes lead to the opening of the TRK gene, leading to the development of cancer. These studies show that larotrectinib is a potentially powerful new treatment for About 5,000 patients with these forms of cancer.

Figure A: Maximum variation in size of different tumor types

Figure B: Results for all patients

In this series of studies, larotrectinib has rapid, potent and long-lasting anti-tumor activity in children and adults, and their solid tumors are fused by TRK without taking into account patient age, tumor tissue and confluent state "Hong said." Our data not only confirm that TRK fusion is a therapeutic target, but also demonstrate the potential of larotrectinib as a TRK fusion-positive cancer therapeutic.

'TRK fusion proteins define a unique subset of molecules that are highly active in tacrolimus and in children and adult advanced solid tumors,' said Hong. "The results show that long-term use of larotrectinib is feasible for TRK-fusion-positive cancer patients. However, screening strategies that include the ability to detect TRK fusion must also continue to evolve to better identify patients who may benefit from this therapy.

Hong added that while a clinically meaningful long-term response was observed in the study patients, follow-up further confirmed the benefit of the drug.